Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Amgen is committed to unlocking the potential of biology for patients suffering fr...
Amgen is committed to unlocking the potential o...
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...
CAVU Biotherapies offers a comprehensive soluti...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
LoveBug Probiotics brings customers an award-winning range of probiotic supplement...
LoveBug Probiotics brings customers an award-wi...
Aldeyra Therapeutics is a biotechnology company devoted to developing and commerci...
Aldeyra Therapeutics is a biotechnology company...
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...
Moleculin Biotech, Inc. is a clinical stage pha...
Join the National Investor Network and get the latest information with your interests in mind.